JP2020524141A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524141A5
JP2020524141A5 JP2019569454A JP2019569454A JP2020524141A5 JP 2020524141 A5 JP2020524141 A5 JP 2020524141A5 JP 2019569454 A JP2019569454 A JP 2019569454A JP 2019569454 A JP2019569454 A JP 2019569454A JP 2020524141 A5 JP2020524141 A5 JP 2020524141A5
Authority
JP
Japan
Prior art keywords
cancer
composition
seq
polypeptide
elane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569454A
Other languages
English (en)
Japanese (ja)
Other versions
JP7189160B2 (ja
JP2020524141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037800 external-priority patent/WO2018232273A1/en
Publication of JP2020524141A publication Critical patent/JP2020524141A/ja
Publication of JP2020524141A5 publication Critical patent/JP2020524141A5/ja
Priority to JP2022192891A priority Critical patent/JP7529754B2/ja
Application granted granted Critical
Publication of JP7189160B2 publication Critical patent/JP7189160B2/ja
Priority to JP2024119305A priority patent/JP2024150679A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569454A 2017-06-15 2018-06-15 がんを処置するための方法および組成物 Active JP7189160B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022192891A JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520325P 2017-06-15 2017-06-15
US62/520,325 2017-06-15
US201762610711P 2017-12-27 2017-12-27
US62/610,711 2017-12-27
PCT/US2018/037800 WO2018232273A1 (en) 2017-06-15 2018-06-15 Methods and compositions for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192891A Division JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020524141A JP2020524141A (ja) 2020-08-13
JP2020524141A5 true JP2020524141A5 (cg-RX-API-DMAC10.html) 2021-09-09
JP7189160B2 JP7189160B2 (ja) 2022-12-13

Family

ID=64659547

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569454A Active JP7189160B2 (ja) 2017-06-15 2018-06-15 がんを処置するための方法および組成物
JP2022192891A Active JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A Pending JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022192891A Active JP7529754B2 (ja) 2017-06-15 2022-12-01 がんを処置するための方法および組成物
JP2024119305A Pending JP2024150679A (ja) 2017-06-15 2024-07-25 がんを処置するための方法および組成物

Country Status (9)

Country Link
US (2) US12564623B2 (cg-RX-API-DMAC10.html)
EP (2) EP3638293B1 (cg-RX-API-DMAC10.html)
JP (3) JP7189160B2 (cg-RX-API-DMAC10.html)
CN (1) CN111032075A (cg-RX-API-DMAC10.html)
AU (1) AU2018285710B2 (cg-RX-API-DMAC10.html)
CA (1) CA3066738A1 (cg-RX-API-DMAC10.html)
DK (1) DK3638293T5 (cg-RX-API-DMAC10.html)
ES (2) ES2962985T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018232273A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119015448A (zh) 2018-12-20 2024-11-26 芝加哥大学 与用于癌症疗法的治疗肽相关的方法和组合物
CN116261592A (zh) * 2020-08-18 2023-06-13 昂希莱斯制药公司 经修饰的丝氨酸蛋白酶前蛋白
EP4199947A4 (en) * 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用
CN115040642B (zh) * 2022-06-30 2025-03-28 德博尔(成都)生物科技有限公司 一种胰弹性蛋白酶的新用途
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用
CN121588088A (zh) * 2025-12-30 2026-03-03 西安交通大学 Sivelestat在制备癌症放射治疗辅助药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU662104B2 (en) 1990-08-03 1995-08-24 Vertex Pharmaceuticals Incorporated Use of crosslinked crystals as a novel form of enzyme immobilization
US5698518A (en) * 1994-03-30 1997-12-16 Oklahoma Medical Research Foundation Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists
WO2003083084A2 (en) * 2002-03-29 2003-10-09 Incyte Corporation Protein modification and maintenance molecules
AU2003249012A1 (en) 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human myeloid leukemia
JP4408615B2 (ja) 2002-10-07 2010-02-03 独立行政法人科学技術振興機構 好酸球カチオン性タンパク質を含有する組成物
US8068990B2 (en) 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2316997T3 (es) 2003-07-21 2009-04-16 F. Hoffmann-La Roche Ag Uso de la proteina proteinasa 3 (prn3) y del inhibidor de la elastasa leucocitaria (ileu) como un marcador para el cancer colorrectal.
US7432419B2 (en) 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
US20060008891A1 (en) 2004-06-23 2006-01-12 The Government Of Usa As Repersented By The Secretary, Department Of Health And Human Services Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)
US20060045881A1 (en) 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2016125330A1 (ja) * 2015-02-02 2016-08-11 原 英彰 網膜再生促進薬

Similar Documents

Publication Publication Date Title
JP2017529059A5 (cg-RX-API-DMAC10.html)
WO2012094653A4 (en) Compositions and methods for macromolecular drug delivery
JP2020509737A5 (cg-RX-API-DMAC10.html)
US20170260246A1 (en) Carcinoma homing peptide (chp), its analogs, and methods of using
CN102936281B (zh) 一种rTRAIL突变体及其海兔毒素偶联物
JP2020517658A5 (cg-RX-API-DMAC10.html)
JP2023145635A (ja) 免疫調節特性を有するペプチド
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
US20240197903A1 (en) Tnf-alpha immunoconjugate therapy for the treatment of brain tumors
CN107206103A (zh) 用于治疗目的的抗体‑脲酶缀合物
CN116789837B (zh) 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
Sui et al. Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy
RU2014145841A (ru) Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы
WO2016186445A1 (ko) 암 세포 표적용 펩타이드 및 이의 용도
JP2022535816A5 (cg-RX-API-DMAC10.html)
Tao et al. Multivalent assembly of nucleolin-targeted F3 peptide potentiates TRAIL's tumor penetration and antitumor effects
CA3109702A1 (en) Peptides and compositions for targeted treatment and imaging
JP2022514354A5 (cg-RX-API-DMAC10.html)
Beswick Bicycles—An entirely new class of therapeutics
CN115028738B (zh) 一种Fc融合蛋白双重靶向降解剂及应用
Wang et al. A bifunctional peptide–selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy
US20220143130A1 (en) Peptides Having Immunomodulatory Properties
JP2023536961A5 (cg-RX-API-DMAC10.html)
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
CN105985447A (zh) 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途